Activity of posaconazole in the treatment of central nervous system fungal infections | Zendy

Punnee Pitisuttithum | Zendy; Ricardo Negroni | Zendy; John R. Graybill | Zendy; Beatriz Bustamante | Zendy; Peter G. Pappas | Zendy; Stanley W. Chapman | Zendy; R S Hare | Zendy; C. Hardalo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activity of posaconazole in the treatment of central nervous system fungal infections

Author(s) -

Punnee Pitisuttithum,

Ricardo Negroni,

John R. Graybill,

Beatriz Bustamante,

Peter G. Pappas,

Stanley W. Chapman,

R S Hare,

C. Hardalo

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki288

Subject(s) - posaconazole , medicine , aspergillosis , coccidioides , coccidioides immitis , mycosis , meningitis , immunology , itraconazole , antifungal , surgery , dermatology

A multinational, multicentre, open-label clinical trial was conducted to evaluate the safety and efficacy of posaconazole, an extended-spectrum triazole antifungal agent, in subjects with invasive fungal infections who had refractory disease or who were intolerant of standard antifungal therapy. In this subanalysis, we report on those subjects in this trial who had a fungal infection that involved the CNS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research